VESALIUS-CV will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
MAIN RESULTS:
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
N Engl J Med. 2026 Jan 8;394(2):117-127.
VESALIUS-CV on ClinicalTrials.gov